In a recent article for Proactive Investors, Angela Harmantas reports on Custom Health's Q3 2026 financial results, highlighting a 220% increase in revenue to US$14.4 million, driven by the first full quarter of contributions from InnovativeRx.
The article also covers gross profit growth of 124%, InnovativeRx's 27% year-over-year revenue increase, and the company's ongoing integration of pharmacy, technology and clinical services.
Harmantas also highlights the acquisition of Spencer Health Solutions, which brought spencer® technology fully in-house, alongside Custom Health's focus on improving margins and operational efficiencies.
Read the full article on Proactive Investors.















